NPS Pharmaceuticals (NPSP) On Watch on Amgen (AMGN) Sensipar News
Tweet
Share
E-mailGet Alerts AMGN Hot Sheet
Price: $442.84 +1.08%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: +5.1%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: +5.1%
Join SI Premium – FREE
NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) is on watch on news the FDA has stopped all pediatric clinical trials of Amgen's (Nasdaq: AMGN) Sensipar after the recent death of a 14-year-old patient in a trial.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amgen (AMGN) call put ratio 1 call to 1.1 puts
- Netlist Loses Appeal In Micron Patent Case - Bloomberg
- Zscaler and CrowdStrike expand partnership with new integrations
Create E-mail Alert Related Categories
Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
